Keros Therapeutics’ (KROS) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research report sent to investors on Thursday morning,RTT News reports. The brokerage currently has a $84.00 target price on the stock. Wedbush also issued estimates for Keros Therapeutics’ Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating on the stock. Bank of America dropped their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Scotiabank assumed coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Price Performance

Shares of KROS traded up $0.74 during mid-day trading on Thursday, reaching $67.91. 624,515 shares of the company’s stock traded hands, compared to its average volume of 370,565. The stock has a market cap of $2.55 billion, a P/E ratio of -13.20 and a beta of 1.23. The stock’s 50-day moving average is $57.74 and its two-hundred day moving average is $52.10. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the company posted ($1.33) earnings per share. The business’s revenue was up 4750.0% on a year-over-year basis. Research analysts predict that Keros Therapeutics will post -4.9 earnings per share for the current year.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Redmile Group LLC acquired a new stake in Keros Therapeutics during the 1st quarter worth about $36,576,000. Darwin Global Management Ltd. grew its position in shares of Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after acquiring an additional 375,523 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock worth $12,990,000 after buying an additional 199,245 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares during the last quarter. Finally, Emerald Advisers LLC acquired a new stake in Keros Therapeutics in the 3rd quarter worth about $9,032,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.